Introduction

Russ B. Altman, David Flockhart, David B. Goldstein

Research output: Contribution to journalArticle

Abstract

Health care is moving toward a more individualized approach that has been termed “personalized medicine.” The underlying causes for this transition are many; they include the ability to genotype and sequence DNA, the increasing emphasis on consumerism among patients, and changes in the pharmaceutical industry worldwide and particularly at the U.S. Food and Drug Administration (FDA) and its sister regulatory agencies around the world. Pharmacogenetics and pharmacogenomics both involve the study of how genetics exerts an impact on drug response phenotype. For our purposes, the term “pharmacogenetics” connotes single genes that dominate the effects on a drug response, whereas “pharmacogenomics” connotes systems of many genes that create complex drug response phenotypes. It is clear that pharmacogenetics and pharmacogenomics are the core elements of the future of personalized medicine. The emergence of robust and effective patient advocacy groups over the past thirty years has led to organized demands by patients for medicines that are more effective and that have fewer side effects. This was fueled by the Institute of Medicine “To Err is Human” report of 1999, which estimated that more than 50,000 Americans die each year because of medical errors, in particular, involving prescription drugs. Health care organizations have registered the clinical and financial dangers inherent in medication errors, and more precise prescribing is now a central part of quality control and even part of the marketing campaigns for hospitals in the United States. The pharmaceutical industry is experiencing the death of the “blockbuster” model of drug development in which one dose of a single medication can be used to treat everyone, including men and women, people of all races, infants, adolescents, adults, and the elderly.

Original languageEnglish
Pages (from-to)xi-xii
JournalUnknown Journal
DOIs
StatePublished - Jan 1 2012

Fingerprint

Pharmacogenetics
Medicine
Pharmaceutical Preparations
Precision Medicine
Drug Industry
Health care
Genes
Delivery of Health Care
Phenotype
Patient Advocacy
Medical Errors
Medication Errors
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Aptitude
Prescription Drugs
DNA sequences
United States Food and Drug Administration
Marketing
Quality Control
Quality control

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Altman, R. B., Flockhart, D., & Goldstein, D. B. (2012). Introduction. Unknown Journal, xi-xii. https://doi.org/10.1017/CBO9781139051194.001

Introduction. / Altman, Russ B.; Flockhart, David; Goldstein, David B.

In: Unknown Journal, 01.01.2012, p. xi-xii.

Research output: Contribution to journalArticle

Altman, RB, Flockhart, D & Goldstein, DB 2012, 'Introduction', Unknown Journal, pp. xi-xii. https://doi.org/10.1017/CBO9781139051194.001
Altman RB, Flockhart D, Goldstein DB. Introduction. Unknown Journal. 2012 Jan 1;xi-xii. https://doi.org/10.1017/CBO9781139051194.001
Altman, Russ B. ; Flockhart, David ; Goldstein, David B. / Introduction. In: Unknown Journal. 2012 ; pp. xi-xii.
@article{bd8e545235854d0b8e679e9d93fd342a,
title = "Introduction",
abstract = "Health care is moving toward a more individualized approach that has been termed “personalized medicine.” The underlying causes for this transition are many; they include the ability to genotype and sequence DNA, the increasing emphasis on consumerism among patients, and changes in the pharmaceutical industry worldwide and particularly at the U.S. Food and Drug Administration (FDA) and its sister regulatory agencies around the world. Pharmacogenetics and pharmacogenomics both involve the study of how genetics exerts an impact on drug response phenotype. For our purposes, the term “pharmacogenetics” connotes single genes that dominate the effects on a drug response, whereas “pharmacogenomics” connotes systems of many genes that create complex drug response phenotypes. It is clear that pharmacogenetics and pharmacogenomics are the core elements of the future of personalized medicine. The emergence of robust and effective patient advocacy groups over the past thirty years has led to organized demands by patients for medicines that are more effective and that have fewer side effects. This was fueled by the Institute of Medicine “To Err is Human” report of 1999, which estimated that more than 50,000 Americans die each year because of medical errors, in particular, involving prescription drugs. Health care organizations have registered the clinical and financial dangers inherent in medication errors, and more precise prescribing is now a central part of quality control and even part of the marketing campaigns for hospitals in the United States. The pharmaceutical industry is experiencing the death of the “blockbuster” model of drug development in which one dose of a single medication can be used to treat everyone, including men and women, people of all races, infants, adolescents, adults, and the elderly.",
author = "Altman, {Russ B.} and David Flockhart and Goldstein, {David B.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1017/CBO9781139051194.001",
language = "English",
pages = "xi--xii",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Introduction

AU - Altman, Russ B.

AU - Flockhart, David

AU - Goldstein, David B.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Health care is moving toward a more individualized approach that has been termed “personalized medicine.” The underlying causes for this transition are many; they include the ability to genotype and sequence DNA, the increasing emphasis on consumerism among patients, and changes in the pharmaceutical industry worldwide and particularly at the U.S. Food and Drug Administration (FDA) and its sister regulatory agencies around the world. Pharmacogenetics and pharmacogenomics both involve the study of how genetics exerts an impact on drug response phenotype. For our purposes, the term “pharmacogenetics” connotes single genes that dominate the effects on a drug response, whereas “pharmacogenomics” connotes systems of many genes that create complex drug response phenotypes. It is clear that pharmacogenetics and pharmacogenomics are the core elements of the future of personalized medicine. The emergence of robust and effective patient advocacy groups over the past thirty years has led to organized demands by patients for medicines that are more effective and that have fewer side effects. This was fueled by the Institute of Medicine “To Err is Human” report of 1999, which estimated that more than 50,000 Americans die each year because of medical errors, in particular, involving prescription drugs. Health care organizations have registered the clinical and financial dangers inherent in medication errors, and more precise prescribing is now a central part of quality control and even part of the marketing campaigns for hospitals in the United States. The pharmaceutical industry is experiencing the death of the “blockbuster” model of drug development in which one dose of a single medication can be used to treat everyone, including men and women, people of all races, infants, adolescents, adults, and the elderly.

AB - Health care is moving toward a more individualized approach that has been termed “personalized medicine.” The underlying causes for this transition are many; they include the ability to genotype and sequence DNA, the increasing emphasis on consumerism among patients, and changes in the pharmaceutical industry worldwide and particularly at the U.S. Food and Drug Administration (FDA) and its sister regulatory agencies around the world. Pharmacogenetics and pharmacogenomics both involve the study of how genetics exerts an impact on drug response phenotype. For our purposes, the term “pharmacogenetics” connotes single genes that dominate the effects on a drug response, whereas “pharmacogenomics” connotes systems of many genes that create complex drug response phenotypes. It is clear that pharmacogenetics and pharmacogenomics are the core elements of the future of personalized medicine. The emergence of robust and effective patient advocacy groups over the past thirty years has led to organized demands by patients for medicines that are more effective and that have fewer side effects. This was fueled by the Institute of Medicine “To Err is Human” report of 1999, which estimated that more than 50,000 Americans die each year because of medical errors, in particular, involving prescription drugs. Health care organizations have registered the clinical and financial dangers inherent in medication errors, and more precise prescribing is now a central part of quality control and even part of the marketing campaigns for hospitals in the United States. The pharmaceutical industry is experiencing the death of the “blockbuster” model of drug development in which one dose of a single medication can be used to treat everyone, including men and women, people of all races, infants, adolescents, adults, and the elderly.

UR - http://www.scopus.com/inward/record.url?scp=84925618132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925618132&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139051194.001

DO - 10.1017/CBO9781139051194.001

M3 - Article

AN - SCOPUS:84925618132

SP - xi-xii

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

ER -